Skip to main content

Affibody to Present at Affinity 2019

Nyhet   •   Jun 17, 2019 08:45 CEST

Solna, Sweden, June 17, 2019. Affibody AB (“Affibody”), a clinical stage biotech company, today announced that Prof. Fredrik Frejd, CSO, will present at the following conference in June:

  • Affinity 2019, Friday, June 28, 2019, 1:40 pm CET, Stockholm, Sweden.

Prof. Frejd will present how the Affibody® platform has been utilized to develop clinical stage bispecific assets with clear differentiation addressing major medical needs. Small size, bispecific format, affinity driven potency, and albumin mediated biodistribution are key advantages that have been translated to clinical benefit.

About Affibody’s Technology Platform

Affibody® molecules are a class of small optimized proteins with high affinity based on a non-immunoglobulin three-helix bundle domain scaffold. Affibody® molecules have certain potentially advantageous features for therapeutic applications including (i) small size resulting in rapid tissue penetration and efficient delivery of higher molar doses for the same mass vs. larger proteins, and (ii) robustness resulting in potential for alternative administration routes. The Albumod™ Platform uses a small optimized protein with an albumin binding domain (5 kDa) with high affinity to albumin (sub pM) to provide half-life extension and a wider distribution profile than antibodies to Affibody® molecules and other therapeutic proteins. The Affibody® technology, which includes the Affibody® molecules (6 kDa size, no Fc-function) and Albumod™ platform, enables modified and enhanced pharmacokinetics through the albumin binding domain, offering the same distribution profile as albumin.

About Affibody

Affibody is a private clinical-stage Swedish biotech company focused on developing into an integrated biopharma company utilizing next generation biotherapeutics based on its unique proprietary technology platforms: Affibody® molecules and Albumod™. The company operates a focused experimental medicine model and currently has three clinical-stage programs. The first two are therapeutic programs that target psoriasis and rare Immunoglobulin G (IgG)-mediated autoimmune diseases. The third program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer. In addition to its portfolio of innovative drug projects, the company offers the half-life extension technology, Albumod™, for outlicensing.